Women with gynaecological sarcoma - a rare cancer that develops in the connective tissues of the female reproductive system - face an uphill battle to access the best treatment and care for their cancer. The report highlights some major issues faced by women with gynaecological sarcoma in the UK, in particular reaching a diagnosis, accessing best care and treatment (in sarcoma specialist centres) and accessing support and information. Whilst the findings relate mainly to cancer services in England, the patient experiences and recommendations will be helpful to any patients and clinician treating women with gynaecological sarcoma throughout Europe. The report has been produced with input from patients and sarcoma clinicians.
A European consensus approach for the management of desmoid based on patients’ and professionals’ expertise
In May 2014 SPAEN initiated a round table meeting bringing together medical experts, researchers and patient representatives to discuss needs and aspects of desmoid tumour treatment. During this meeting, a European consensus approach has been initialized, and on the basis of this meeting a consensus paper has been coordinated, which has now been published by the EJC as a combined SPAEN and EORTC / STBSG initiative based on patients’ and patient advocates’ and professionals’ expertise. Read more
During this year’s Annual Conference, SPAEN also held its Annual General Meeting (AGM) with elections to the SPAEN Board of Directors. The assembly confirmed that the previous Board Members should retain their places on the Board for the next 4 years and elected new members to the Board. The newly established Board will now be jointly chaired by Estelle Lecointe from France and Markus Wartenberg from Germany.
AEAS (Spanish Association for Sarcoma´s Affected) and Mª Paz Jiménez Casado Foundation, once again join its efforts to keep fighting against this rare type of cancer, organizing the 2nd Sarcoma National Day, that will be held in Madrid at 20th of September, endorsed by GEPAC, GEIS, SEMERGEN and COAM.
30 July 2014 - The oncology compound Stivarga® (Regorafenib) from Bayer has been approved by the European Commission (EC) for the treatment of adult patients with unresectable or metastatic GIST (gastrointestinal stromal tumours) who progressed on or are intolerant to prior treatment with Imatinib (Glivec®) and Sunitinib (Sutent®).
Further to the launch of the Paediatric, Adolescent, Wild-type and Syndromic GIST clinic at Addenbrookes Hospital Cambridge UK, earlier this year the second clinic happened in early August. The second clinic involved seven female patients, x5 in the range 16 -25 and x2 aged 25 plus, from a variety of UK locations.